CALL/VERTEX PHARMACEUTICALS/600/0.1/17.01.25 | Real-time BOERSE MUENCHEN 08:25:16 2024-06-11 EDT | ||
| 0.9 EUR | 0.00% |
|
| Current month | +78.93% | ||
| 1 month | +220.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 0.9 | 0.00% |
| 24-06-10 | 0.9 | -7.22% |
| 24-06-07 | 0.97 | +3.19% |
| 24-06-06 | 0.94 | +3.30% |
| 24-06-05 | 0.91 | +13.75% |
Real-time BOERSE MUENCHEN
Last update June 11, 2024 at 08:25 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP93AG |
| ISIN | DE000GP93AG2 |
| Date issued | 2023-07-17 |
| Strike | 600 $ |
| Maturity | 2025-01-17 (220 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.3 € |
| Spread % | 25.86% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483.3
USD
Average target price
463.5
USD
Spread / Average Target
-4.09%
- Stock Market
- Warrants
- Warrant
